{"page_content": "ESG R eport 2021Number of fatalities associated with products as reported in the \nFDA Adverse Event Reporting System\nSASB: HC-BP-250A.2\nThis information for our products can be found in the FDA\u2019s Adverse \nEvent Reporting System here .\nNumber of recalls issued, total units recalled\nSASB: HC-BP-250A.3\nAgios has not been subject to any FDA recalls.\nNumber of FDA enforcement actions taken in response to \nviolations of current Good Manufacturing Practices (cGMP),  \nby type\nSASB: HC-BP-250A.5\nAgios has not had any GMP violations or FDA enforcement actions.\nDRUG SAFETY AND COUNTERFEIT DRUGS\n13", "metadata": {"source": "NASDAQ_AGIO_2020.pdf", "page": 12, "parser": "pypdf", "split_method": "page", "run_time": "2024-05-29 08:35:04"}, "type": "Document"}